ConductScience.org, home

Paper29803003

Development of novel amino-quinoline-5,8-dione derivatives as NAD(P)H:quinone oxidoreductase 1 (NQO1) inhibitors with potent antiproliferative activities.

Ling Y and 10 others. Eur J Med Chem, 2018. Cited by 25 papers, by iCite.

Cite this record

ConductScience Library. Development of novel amino-quinoline-5,8-dione derivatives as NAD(P)H:quinone oxidoreductase 1 (NQO1) inhibitors with potent antiproliferative activities. Papers, record 29803003. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29803003

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Development of novel amino-quinoline-5,8-dione derivatives as NAD(P)H:quinone oxidoreductase 1 (NQO1) inhibitors with potent antiproliferative activities.
PubMed
Journal
Eur J Med Chem
PubMed
Year
2018
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
25
iCite
Relative citation ratio, by iCite
1.27
iCite
Revised in PubMed
2020-02-25
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ling YYong
2Yang QXQiu-Xing
3Teng YNYu-Ning
4Chen SShi
5Gao WJWei-Jie
6Guo JJing
7Hsu PLPei-Ling
8Liu YYue
9Morris-Natschke SLSusan L
10Hung CCChin-Chuan
11Lee KHKuo-Hsiung

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Enzyme InhibitorsMajor topic
NAD(P)H Dehydrogenase (Quinone)Major topic
QuinolonesMajor topic
Cell Line, Tumor
Cell Proliferation
Dose-Response Relationship, Drug
Drug Screening Assays, Antitumor
Humans
Molecular Structure
Structure-Activity Relationship

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
R01 CA177584NCI NIH HHSUnited StatesR01CA177584PubMed

Source NIH RePORTER

Download CSV of grants

References26

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
111563930Indolequinone antitumor agents: correlation between quinone structure and rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase. Part 2.J Med Chem2001https://conductscience.org/library/papers/11563930PubMed
211674079A Biomimetic Approach to the Discorhabdin Alkaloids: Total Syntheses of Discorhabdins C and E and Dethiadiscorhabdin D.J Org Chem1999https://conductscience.org/library/papers/11674079PubMed
311693537Effects of 6-arylamino-5,8-quinolinediones and 6-chloro-7-arylamino-5,8-isoquinolinediones on NAD(P)H: quinone oxidoreductase (NQO1) activity and their cytotoxic potential.Arch Pharm Res2001https://conductscience.org/library/papers/11693537PubMed
411888914Subcellular localization of NAD(P)H:quinone oxidoreductase 1 in human cancer cells.Cancer Res2002https://conductscience.org/library/papers/11888914PubMed
51324793Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin Cł.Cancer Res1992https://conductscience.org/library/papers/1324793PubMed
615028260Novel quinolinequinone antitumor agents: structure-metabolism studies with NAD(P)H:quinone oxidoreductase (NQO1).Bioorg Med Chem2004https://conductscience.org/library/papers/15028260PubMed
715245776DT-diaphorase: a target for new anticancer drugs.Cancer Treat Rev2004https://conductscience.org/library/papers/15245776PubMed
816302813Novel lavendamycin analogues as antitumor agents: synthesis, in vitro cytotoxicity, structure-metabolism, and computational molecular modeling studies with NAD(P)H:quinone oxidoreductase 1.J Med Chem2005https://conductscience.org/library/papers/16302813PubMed
916689993Reactive oxygen species: role in the development of cancer and various chronic conditions.J Carcinog2006https://conductscience.org/library/papers/16689993PubMed
1017160708The signaling mechanism of ROS in tumor progression.Cancer Metastasis Rev2006https://conductscience.org/library/papers/17160708PubMed
1118457384Lavendamycin antitumor agents: structure-based design, synthesis, and NAD(P)H:quinone oxidoreductase 1 (NQO1) model validation with molecular docking and biological studies.J Med Chem2008https://conductscience.org/library/papers/18457384PubMed
1220149966Synthesis, metabolism and in vitro cytotoxicity studies on novel lavendamycin antitumor agents.Bioorg Med Chem2010https://conductscience.org/library/papers/20149966PubMed
1323574193Synthesis of new quinolinequinone derivatives and preliminary exploration of their cytotoxic properties.J Med Chem2013https://conductscience.org/library/papers/23574193PubMed
1424079832How does the metabolism of tumour cells differ from that of normal cells.Biosci Rep2013https://conductscience.org/library/papers/24079832PubMed
1524287781Modulation of oxidative stress as an anticancer strategy.Nat Rev Drug Discov2013https://conductscience.org/library/papers/24287781PubMed
1625517383Targeting mitochondria metabolism for cancer therapy.Nat Chem Biol2015https://conductscience.org/library/papers/25517383PubMed
1726276080Pyrroloquinoline quinone-conferred neuroprotection in rotenone models of Parkinson's disease.Toxicol Lett2015https://conductscience.org/library/papers/26276080PubMed
1826689625ZT-25, a new vacuolar H(+)-ATPase inhibitor, induces apoptosis and protective autophagy through ROS generation in HepG2 cells.Eur J Pharmacol2016https://conductscience.org/library/papers/26689625PubMed
1927341379Synthesis and antitumor activity of selenium-containing quinone-based triazoles possessing two redox centres, and their mechanistic insights.Eur J Med Chem2016https://conductscience.org/library/papers/27341379PubMed
2028006669Alkynyloxy derivatives of 5,8-quinolinedione: Synthesis, in vitro cytotoxicity studies and computational molecular modeling with NAD(P)H:Quinone oxidoreductase 1.Eur J Med Chem2017https://conductscience.org/library/papers/28006669PubMed

See all 26 referencesDownload CSV of references

Cited by15

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 25 citations.

PMIDTitleJournalYearIn PapersSource
42915840Illuminating the Disease Landscape: Human Oxidoreductase-Targeted Imaging and Quantification Agents for Precision Imaging and Activity Determination.Acc Chem Res2026https://conductscience.org/library/papers/42915840PubMed
40613877Recent advances in drug repositioning and rediscovery for different therapeutic activities utilizing updated technological approaches.Mol Divers2026https://conductscience.org/library/papers/40613877PubMed
40002465Natural Source of Drugs Targeting Central Nervous System Tumors-Focus on NAD(P)H Oxidoreductase 1 (NQO1) Activity.Brain Sci2025https://conductscience.org/library/papers/40002465PubMed
38173200Exploring the Therapeutic Marvels: A Comprehensive Review on the Biological Potential of Quinoline-5,8-Dione.Med Chem2024https://conductscience.org/library/papers/38173200PubMed
37049894Anticancer Properties of 3-Dietoxyphosphorylfuroquinoline-4,9-dione.Molecules2023https://conductscience.org/library/papers/37049894PubMed
36982753Analogues of Anticancer Natural Products: Chiral Aspects.Int J Mol Sci2023https://conductscience.org/library/papers/36982753PubMed
36267290NQO1 protects against clioquinol toxicity.Front Pharmacol2022https://conductscience.org/library/papers/36267290PubMed
36234741Hybrids of 1,4-Quinone with Quinoline Derivatives: Synthesis, Biological Activity, and Molecular Docking with DT-Diaphorase (NQO1).Molecules2022https://conductscience.org/library/papers/36234741PubMed
34071116Lipophilicity, Pharmacokinetic Properties, and Molecular Docking Study on SARS-CoV-2 Target for Betulin Triazole Derivatives with Attached 1,4-Quinone.Pharmaceutics2021https://conductscience.org/library/papers/34071116PubMed
33536926Novel Hybrid CHC from β-carboline and N-Hydroxyacrylamide Overcomes Drug-Resistant Hepatocellular Carcinoma by Promoting Apoptosis, DNA Damage, and Cell Cycle Arrest.Front Pharmacol2020https://conductscience.org/library/papers/33536926PubMed
33260896Biological Properties of New Chiral 2-Methyl-5,6,7,8-tetrahydroquinolin-8-amine-based Compounds.Molecules2020https://conductscience.org/library/papers/33260896PubMed
32900354Tailored Quinolines Demonstrate Flexibility to Exert Antitumor Effects through Varied Mechanisms-A Medicinal Perspective.Anticancer Agents Med Chem2021https://conductscience.org/library/papers/32900354PubMed
31978040NF-κB Phosphorylation Inhibition Prevents Articular Cartilage Degradation in Osteoarthritis Rats via 2-Aminoquinoline.Med Sci Monit2020https://conductscience.org/library/papers/31978040PubMed
317394965,8-Quinolinedione Scaffold as a Promising Moiety of Bioactive Agents.Molecules2019https://conductscience.org/library/papers/31739496PubMed
30518535NAD(P)H quinone oxidoreductase (NQO1): an enzyme which needs just enough mobility, in just the right places.Biosci Rep2019https://conductscience.org/library/papers/30518535PubMed

Download CSV of cited by

Genes7

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/29803003

GET https://conductscience.org/api/papers/v1/29803003/references?page=2